AXGN:NASDAQ
AxoGen, Inc Common Stock
55,93Â US$
arrow_upward
+0,96%(+0,53) 1D
13 nën, 4:00:01 m.d., GMT-5 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për AXGN...
Hap
55,88Â US$
I lartë
57,46Â US$
I ulët
55,01Â US$
Kapitalizimi i tregut
3,34Â mld
Vëllimi mesatar
1,98Â mln
Vëllimi
1,38Â mln
Maksimumi 52-javor
59,72Â US$
Minimumi 52-javor
23,00Â US$
Fitimet për aksion
-0,68Â US$
Beta
1,21
Aksionet në qarkullim
59,73Â mln
Numri i punonjësve
622
Hap
55,88Â US$
I lartë
57,46Â US$
I ulët
55,01Â US$
Kapitalizimi i tregut
3,34Â mld
Vëllimi mesatar
1,98Â mln
Vëllimi
1,38Â mln
Maksimumi 52-javor
59,72Â US$
Minimumi 52-javor
23,00Â US$
Fitimet për aksion
-0,68Â US$
Beta
1,21
Aksionet në qarkullim
59,73Â mln
Numri i punonjësve
622
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Zacks
·
1 ditë më parë
AxoGen (AXGN) is a Great Momentum Stock: Should You Buy?
Investing.com
·
2 ditë më parë
AxoGen at Canaccord forum: growth plan widens beyond nerve repair
Profili
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Rreth AxoGen, Inc Common Stock
Drejtori ekzekutiv-
Punonjësit622
Themeluar më2002
SeliaAlachua, Florida, Shtetet e Bashkuara të Amerikës
SektoriHealth Care
IndustriaMedical device
Uebsajtiaxogeninc.com